Scottish Trace Element & Micronutrient Reference Laboratory

Scotland's specialised laboratory for trace elements and vitamins in health and disease

Vitamin B6

Vitamin B6 is a water soluble vitamin. The main circulating forms of vitamin B6 are pyridoxal (PL) and pyridoxal 5’- phosphate (PLP). These two forms are detectable in both plasma and blood cells. The functional form is PLP. It acts as a coenzyme for many enzymes in the body and is involved in metabolism of proteins, carbohydrates, fats and homocysteine and synthesis of several neurotransmitters (e.g. serotonin, epinephrine and norepinephrine) and haem. These enzymes include decarboxylases, aminotransferases and glycogen phosphorylase. Especially diverse are PLP-dependent enzymes involved in amino acid metabolism. Vitamin B6 also influences the immune system and may modulate action of some steroid hormones.


Deficiency and Toxicity
Body stores of vitamin B6 are low (20-30mg), so deficiency can develop fairly quickly when intake is inadequate or losses are excessive.


Specific vitamin B6 deficiency is rare; it usually occurs in combination with other water soluble vitamin deficiencies as a result of malabsorption states, increased losses (e.g. during renal dialysis) and as a result of inadequate nutrition. However, interaction with certain drugs (e.g. isoniazid, penicillamine and hydrocortisone) may induce specific vitamin B6 deficiency.


Deficiency is associated with various symptoms: irritability, depression, confusion, inflammation of the tongue, sores or ulcers of the mouth and epileptiform convulsions. Haematological manifestations may also occur and include a normocytic, microcytic or sideroblastic anaemia. Vitamin B6 deficiency is associated with hyperhomocysteinaemia which is an independent risk factor for cardiovascular disease.


Although no adverse effects have been linked to high dietary intake of vitamin B6, chronic high doses of vitamin B6 supplements have been linked to sensory neuropathy and dermatological lesions.


Assessment of status
Plasma vitamin B6 (PLP) is mainly bound to albumin and so concentrations can fall in the presence of systemic inflammatory response independent of vitamin B6 nutritional status. This is because plasma albumin concentrations fall as part of the systemic inflammatory response and also perhaps due to the redistribution of PLP and increased uptake by tissues. Hypoalbuminemia can also lower plasma PLP concentration independent of its nutritional status.


Work done by STEMDRL has shown that the red cell PLP concentration is unaffected by systemic inflammatory response in patients 48 hours after undergoing elective surgery for knee arthroplasty,76 whereas the plasma PLP concentration decreases significantly (~50%; see Table 1). This reduction is dependent on the magnitude of the systemic inflammatory response (see Table 2).28 Red cell PLP also reflects supplementation in patients with critical illness.79 We therefore recommend the measurement of PLP in red cells in patients that have evidence of systemic inflammatory response. Results are expressed as pmoles of PLP per g of haemoglobin.


We routinely only report red cell PLP for assessment of vitamin B6 status. However, if required, plasma PLP, its metabolite pyridoxic acid (PA) and pyridoxal (PL) can be measured to assess vitamin B6 status in patients who are non inflamed and for research studies. Measurement of plasma PLP and PA is particulary useful to aid in the diagnosis of hypophosphatasia, a disorder characterized by low levels of alkaline phosphatase (ALP). Markedly elevated concentrations of plasma PLP with a low plasma concentration of PA and very high PLP:PA ratio are observed in cases of hypophosphatasia.

Recommended Daily Allowance
Adults: 1.3 mg/day but requirements depend on protein intake.


Effect of Systemic Inflammatory Response on Plasma and Red Cell Vitamin B6 Concentrations

Table 1: Baseline, peak/ trough and day 7 concentrations of CRP, plasma and red cell pyridoxal 5 phosphate (PLP) and albumin following elective surgery for knee arthroplasty (n = 20).76 Median (range).

 

Baseline values

(0 h)
 

Peak/trough

(48 h)
 

Final values

(168 h)
 

Friedman

(0–168 h)
 

C-reactive protein (mg/L)        <6 (<6–<6)             170 (70–242)        31 (<6–168)    <0.001
Plasma PLP (nmol/L) 25 (17-36) 13 (10-18) 23 (13-29) <0.001
Albumin (g/L) 41 (38-45) 36 (24-39) 39 (34-43) <0.001
Red cell PLP
(pmol/g Hb)
295 (210-550) 320 (307-544) 320 (240-580) 0.409

 

Table 2: Distribution of median plasma vitamin B6 concentrations according to increments of CRP concentrations (n = 796).28

CRP concentration

(mg/L)

n

Median plasma vitamin B6 concentration

(nmol/L)

P
≤5        401       48 -
>5-10 102 27 <0.001
>10-20 83 32 <0.01
>20-40 67 24 <0.001
>40-80 61 18 <0.001
>80 82 15 <0.001

 

Sample Requirements and Reference Ranges for Vitamin B6

Sample Type

Whole blood or packed red blood cells (please label tube as red cells; fasting sample preferred*).


Plasma (fasting sample) – for diagnosis/investigation of hypophosphatasia only. Please write ‘plasma PLP/PA ratio’ on request form.

Container Lithium heparin (non-gel) or EDTA. Lithium heparin gel tubes unsuitable.
Precautions Light-sensitive; wrap in tin foil (red cell and plasma).
Red cell: Send by first class post within 72 hours. If delivery to Glasgow is outwith 72 hours of sample collection, prepare red cells (minimum volume 300 µL) by removing plasma and buffy layer (mark clearly on tube that they are red cells) and store frozen until sending and then send by first class post (ice or dry ice not required).
Plasma: Patient must not be on vitamin B6 supplements for at least 2 weeks prior to sample collection. Store plasma frozen until sending and then send by first class post (ice or dry ice not required).
Minimum volume*

Red cell: 1 mL whole blood or 400 µL** of red cells*** (Vitamin B2 can be analysed simultaneously on this volume).

Plasma: 600 µL**

Reference range Red cell PLP***: 250-680 pmol/g Hb80
<200 pmol/g Hb (At risk of deficiency)
>2000 pmol/g Hb (over supplementation)
>4000 pmol/g Hb (risk of toxicity)

Plasma (for diagnosis/investigation of hypophosphatasia)

PLP: 20 – 140 nmol/L80

PA: 9 - 60 nmol/L80

PLP:PA ratio: <5

Mean turnaround time Red cell: 4.5 days
Method HPLC with fluorimetric detection80
Traceability Calibrated using commercially available standard manufactured in accordance with EN ISO 17511:2003 “In vitro diagnositic medical devices. Measurement of quantities in biological samples. Metrological traceability of values assigned to calibrators and control materials”.
Intermediate Precision (CV) Red Cell: 6.4% at 348 pmol/g Hb, 6.5% at 2275 pmol/g Hb
Measurement Uncertainty, U Red cell: 348 ± 45 pmol/g Hb, 2275 ± 297 pmol/g Hb
Analytical Goals (CV) Red cell: Acceptable 10.5%, Desirable 7%****
EQA Scheme

INSTAND whole blood EQA scheme, Düsseldorf, Germany.

INSTAND plasma EQA scheme participation pending.

* Ideally a fasting sample should be collected, especially if the patient is receiving oral or parenteral vitamin B6 supplementation. If this is not possible, sample should be taken at least 8 hours post treatment for patients receiving oral supplementation or TPN.
** Absolute minimum volume; this volume is insufficient to carry out repeat analysis if analysis fails.
*** Please contact the Laboratory if vitamin B6 in plasma is required.
**** Goal origin: biological variation.71

 

References

Content © 2004-2017. Scottish Trace Element and Micronutrient Diagnostic and Research Laboratory
website by plexus media